Alnylam Posts Mid-Stage Study Data From Regeneron-Partnered Kidney Disease Drug

Alnylam Pharmaceuticals Inc ALNY announced results from a Phase 2 study of cemdisiran for immunoglobulin A nephropathy (IgAN).
Cemdisiran is an investigational RNAi therapeutic targeting the C5 component of the complement pathway and is under development in collaboration with Regeneron Pharmaceuticals Inc REGN.
New results demonstrated a 36% reduction in 24-hour urine total protein and a higher proportion, 32% versus 13%, of patients treated with cemdisiran as compared to those on placebo, respectively, achieving greater than or equal to 50% reduction in 24-hour UPCR.
Related: Why Alnylam Pharma Shares Are Trading Higher During Premarket Session.
Spot urine data were consistent with 24-hour urine data, with the initial onset of treatment effect emerging as early as Week 8 and remaining stable over time. Patients on cemdisiran achieved a 46% placebo-adjusted reduction from baseline in spot UPCR at 32 weeks.
The results showed that cemdisiran was generally well tolerated with no adverse events. One death occurred in the cemdisiran arm due to cardiorespiratory collapse; this was not considered related to the study drug.
Price Action: ALNY shares are down 0.68% at $209.51 on the last check Monday.